MAGNEsium trial in children (MAGNETIC): A randomised, placebo-controlled trial and economic evaluation of nebulised magnesium sulphate in acute severe asthma in children

Health Technology Assessment

Volumn 17, Issue 45, 2013, Pages

  Powell, C V E ^a   Kolamunnage Dona, R ^b   Lowe, J ^b   Boland, A ^b   Petrou, S ^c   Doull, I ^d   Hood, K ^a   Williamson, P R ^b  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c UNIVERSITY OF WARWICK   (United Kingdom)

^d CHILDREN S HOSPITAL FOR WALES   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; IPRATROPIUM BROMIDE; ISOTONIC SOLUTION; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MAGNESIUM SULFATE; OXYGEN; PLACEBO; SALBUTAMOL; SODIUM CHLORIDE;

ABDOMINAL PAIN; ABSENCE OF SIDE EFFECTS; ACUTE DISEASE; ARTICLE; ASTHMA; ASTHMA SEVERITY SCORE; BACKACHE; BLOOD PER RECTUM; BLOOD PRESSURE MEASUREMENT; CLINICAL ASSESSMENT; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; CYANOSIS; DIARRHEA; DISEASE DURATION; DISEASE SEVERITY; DIZZINESS; DROWSINESS; DRUG COST; DRUG WITHDRAWAL; ECONOMIC EVALUATION; ECZEMA; ENDOBRONCHIAL INTUBATION; EUROPEAN QUALITY OF LIFE 5 DIMENSIONS; FOOD ALLERGY; HAY FEVER; HEADACHE; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH ECONOMICS; HEART ARRHYTHMIA; HOSPITAL ADMISSION; HOT FLUSH; HUMAN; HYPOKALEMIA; HYPOREFLEXIA; HYPOTENSION; INHALER; INTENSIVE CARE UNIT; LENGTH OF STAY; MONOTHERAPY; MUSCLE CRAMP; NAUSEA; NEBULIZER; NERVOUSNESS; PEDIATRIC HOSPITAL; PRURITUS; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; QUALITY OF LIFE INDEX; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RESPIRATION DEPRESSION; RISK BENEFIT ANALYSIS; SCORING SYSTEM; SIDE EFFECT; SILENT CHEST; SOMNOLENCE; SYSTEMATIC REVIEW; TACHYCARDIA; TEETH WHITENING; THORAX DISEASE; THORAX PAIN; TREATMENT OUTCOME; TREATMENT RESPONSE; TREMOR; UNITED KINGDOM; VACANT EPISODE; VOMITING; CHILD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; EMERGENCY HEALTH SERVICE; FEMALE; MALE; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; SEVERITY OF ILLNESS INDEX;

ACUTE DISEASE; ASTHMA; BRONCHODILATOR AGENTS; CHILD; CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; EMERGENCY SERVICE, HOSPITAL; FEMALE; HUMANS; MAGNESIUM SULFATE; MALE; NEBULIZERS AND VAPORIZERS; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX;

EID: 84886379061     PISSN: 13665278     EISSN: 20464924     Source Type: Journal    
DOI: 10.3310/hta17450     Document Type: Article

References (86)

1. Sennhauser F. The burden of asthma in children. Paediatr Resp Rev 2005;6:2-7. http://dx.doi.org/10.1016/j.prrv.2004.11.001
2. Department of Health (DoH). URL: www.dh.gov.uk (accessed 12 April 2013).
3. British Thoracic Society (BTS), Scottish Intercollegiate Guidelines Network (SIGN). British Guideline on the Management of Asthma. A national clinical guideline. London: BTS; revised May 2011.
4. Mohammed S, Goodacre S. Intravenous and nebulised magnesium sulphate for acute asthma: systematic review and meta-analysis. EMJ 2007;24:823-30. http://dx.doi.org/10.1136/emj.2007.052050
5. Goodacre S. The 3Mg Study: a randomised trial of intravenous or nebulised magnesium sulphate versus placebo for acute severe asthma. URL: www.sheffield.ac.uk/scharr/sections/hsr/emergency/3mg (accessed March 2012).
6. Blitz M. Inhaled magnesium sulphate in the treatment of acute asthma (a review). Cochrane Database Syst Rev 2005;3:CD003898.
7. Blitz M, Blitz S, Hughes R, Diner B, Beasley R, Knopp J, et al. Aerosolised magnesium sulphate for acute asthma: a systematic review. Chest 2005;128:337-44.
8. Cairns CB, Kraft M. Magnesium attenuates the neutrophil respiratory burst in adult asthmatic patients. Acad Emerg Med 1996;3:1093-7. http://dx.doi.org/10.1111/j.1553-2712.1996.tb03366.x
9. Gourgoulianis KI, Chatziparasidis G, Chatziefthimiou A, Molyvdas PA. Magnesium as a relaxing factor of airway smooth muscles. J Aerosol Med 2001;14:301-7. http://dx.doi.org/10.1089/089426801316970259
10. Silverman R. Intravenous magnesium sulphate in the treatment of acute severe asthma. A multi-centre randomised controlled trial. Chest 2002;122:489-97.
11. Rowe BH, Bretzlaff JA, Bourdon C, Bota GW, Camargo CA Jr. Magnesium sulfate for treating exacerbations of acute asthma in the emergency department. Cochrane Database Syst Rev 2000;2: CD001490. http://dx.doi.org/10.1002/14651858.CD001490
12. Hill J, Britton J. Dose-response relationship and time-course of the effect of inhaled magnesium sulphate on airflow in normal and asthmatic subjects. Br J Clin Pharmacol 1995;40:539-44. http://dx.doi.org/10.1111/j.1365-2125.1995.tb05798.x
13. Zanddsteeg AMG, Hirman P, Pamsa HR, Yska JP, ten Brinke A. Effect of MgSO4 on FEV1 in stable severe asthma patients with chronic airflow limitation. Magnesium Res 2009;22:256-61.
14. Mangat H. Nebulised magnesium sulphate versus nebulised salbutamol in acute bronchial asthma: a clinical trial. Eur Resp J 1998;38:341-4.
15. Nannini L, Pendino J, Corna R, Mannarino S, Quispe R. Magnesium sulphate as a vehicle for nebulised salbutamol in acute asthma. Am J Med 2000;108:193-7.
16. Hughes R. The use of isotonic nebulised magnesium as an adjuvant to salbutamol. Lancet 2003;361:2114-17. http://dx.doi.org/10.1016/S0140-6736(03)13721-X
17. Bessmertny O, DiGregorio R, Cohen H, Becker E, Looney D, Golden J, et al. A randomized clinical trial of nebulised magnesium sulphate in addition to albuterol in the treatment of acute mild-to-moderate asthma exacerbations in adults. Ann Emerg Med 2002;39:585-91.
18. Mahajan P, Haritos D, Rosenberg N, Thomas R. Comparison of nebulised magnesium sulphate plus albuterol plus saline in children with exacerbations of mild to moderate asthma. J Emerg Med 2004;27:21-5.
19. Meral A. Inhalation therapy with MgSO4. Turk J Pediatr 1996;38:169-75.
20. Costello J, Howes M. Nebulised magnesium in asthma. Emerg Med J 2004;21:586-7. http://dx.doi.org/10.1136/emj.2004.017939
21. Kokturk N, Turktas H, Kara P, Mullaoglu S, Yilmaz F, Karamercan A. A randomized clinical trial of magnesium sulphate as a vehicle for nebulized salbutamol in the treatment of moderate to severe asthma attacks. Pulm Pharmacol Ther 2005;18:416-21. http://dx.doi.org/10.1016/j.pupt.2005.03.003
22. Aggarwal P, Sharad S, Handa R, Dwiwedi SN, Irshad M. Comparison of nebulised magnesium sulphate and salbutamol combined with salbutamol alone in the treatment of acute bronchial asthma: a randomised study. Emerg Med J 2006;23:358-62. http://dx.doi.org/10.1136/emj.2005.026203
23. Drobina BJ, Kostic MA, Roos JA. Nebulized magnesium has no benefit in the treatment of acute asthma in the emergency department. Acad Emerg Med 2006;13:S26. http://dx.doi.org/10.1197/j.aem.2006.03.047
24. Dwan K, Gamble C, Kolamunnage-Dona R, Mohammed S, Powell C, Williamson P. Assessing the potential for reporting bias in a review: a tutorial. Trials 2010;11:52-62. http://dx.doi.org/10.1186/1745-6215-11-52
25. Rolla G, Bucca C, Arossa W, Bugiani M. Magnesium attenuates methacholine-induced bronchoconstriction in asthmatics. Magnesium 1987;6:201-4.
26. Rolla G, Bucca C, Caria E. Dose-related effect of inhaled magnesium-sulfate on histamine bronchial challenge in asthmatics. Drugs Exp Clin Res 1988;14:609-12.
27. Ashtekar CS, Powell C, Hood K, Doull I. Magnesium nebuliser trial (MAGNET): a randomised doubleblind placebo controlled pilot study in severe acute asthma. Arch Dis Child 2008;93:A100-6.
28. Conway S. Admission to hospital with asthma. Arch Dis Child 1985;60:636-9. http://dx.doi.org/10.1136/adc.60.7.636
29. Bishop J, Carlin J, Nolan T. Evaluation of the properties and reliability of the clinical severity scale for acute asthma in children. J Clin Epidemiol 1992;45:71-6. http://dx.doi.org/10.1016/0895-4356(92)90190-X
30. Yung M, South M, Byrt T. Evaluation of an asthma severity score. JPCH 1996;32:261-4.http://dx.doi.org/10.1111/j.1440-1754.1996.tb01567.x
31. Fischl, MA, Pitchenik A, Gardner LB. An index predicting relapse and need for hospitalization in patients with acute bronchial asthma. N Engl J Med 1981;305:783-9. http://dx.doi.org/10.1056/NEJM198110013051402
32. Powell C, Dwan K, Milan SJ, Beasley R, Hughes R, Knopp-Sihota JA, et al. Inhaled magnesium sulfate in the treatment of acute asthma. Cochrane Database Syst Rev 2012;12:CD003898. http://dx.doi.org/10.1002/14651858.CD003898.pub5
33. Abreu-Gonzalez J, Rodríguez-Díaz CY. Magnesium and bronchodilator effect of beta-adrenergic. Am J Resp Crit Care Med 2002;165:A185.
34. Gaur SN, Singh A, Kumar R. Evaluating role of inhaled magnesium sulphate as an adjunct to salbutamol and ipratropium in severe acute asthma. Chest 2008;134:91003s.
35. Gallegos-Solórzano MC, Pérez-Padilla R, Hernández-Zenteno RJ. Usefulness of inhaled magnesium sulfate in the co-adjuvant management of severe asthma crisis in an emergency department. Pulm Pharmacol Ther 2010;23:432-7.
36. Neki NS. A comparative clinical efficacy and safety profile of inhaled magnesium sulphate and salbutamol nebulisations in severe asthma. Indian J Allergy Asthma Immunol 2006;20:131.
37. Khashabi J, Asadolahi S, Karamiyar M, Salari L.S. Comparison of magnesium sulfate to normal saline as a vehicle for nebulized salbutamol in children with acute asthma: a clinical trial. European Respiratory Society Annual Congress, 2008, Berlin, abstract no. 4597.
38. Dadhich P, Tailor M, Gupta ML, Gupta R. Magnesium sulphate nebulisation in acute severe asthma. Indian J Allergy Asthma Immunol 2005;19:117.
39. Rafai Z. Systematic review of outcomes in acute asthma in childhood. MSc Thesis. Cardiff: Cardiff University; 2012.
40. Gorelick MH, Stevens MW, Schultz T, Scribano PV. Difficulty in obtaining peak expiratory flow measurements in children with acute asthma. Pediatr Emerg Care 2004;20:22-6. http://dx.doi.org/10.1097/01.pec.0000106239.72265.16
41. Van der Mindt DA, Nagelkerke AF, Bouter LM, Dankert-Roelse JE, Veerman JP. Clinical scores for acute asthma in preschool children: a review of the literature. Epidemiology 1994;47:635-46.
42. Birken CS, Parkin PC, Macarthur C. Asthma severity scores for preschoolers displayed weaknesses in reliability, validity and responsiveness. J Clin Epidemiol 2004;57:1177-81. http://dx.doi.org/10.1016/j.jclinepi.2004.02.016
43. Kelly AM, Kerr D, Powell C. Is severity assessment after one hour of treatment better for predicting the need for admission in acute asthma? Respir Med 2004;98:777-81. http://dx.doi.org/10.1016/j.rmed.2004.01.008
44. Elashoff JD. nQuery Advisor Version 4.0 User's Guide. Los Angeles, CA: Statistical Solutions; 2000. URL: http://statistical-solutions-software.com/wp-content/uploads/nQ70_versio n2_manual.pdf (accessed 12 April 2013).
45. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. Part I: Introduction and design. Br J Cancer 1976;34:585-612. http://dx.doi.org/10.1038/bjc.1976.220
46. National Institute for Health and Care Excellence (NICE). Guide to the methods of technology appraisal. Sections 5.4.1 to 5.4.4. 2008. URL: www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf (accessed 12 April 2013).
47. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the economic evaluation of health care programmes. 3rd edn. Oxford: Oxford University Press; 2005.
48. Curtis L. Unit costs of health and social care 2009. Canterbury: PSSRU, University of Kent; 2009. URL: www.pssru.ac.uk/uc/uc2009contents.htm (accessed 12 April 2013).
49. Department of Health (DoH). NHS reference costs 2009-2010. London: DoH; 2011. URL: www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPoli cyAndGuidance/DH_111591 (accessed 12 April 2013).
50. British Medical Association and Royal Pharmaceutical Society of Great Britain. British national formulary. No. 60, September 2010. London: BMA and RPS; 2010. URL: www.bnf.org/bnf/(accessed 12 April 2013).
51. Kind P, Hardman G, Macran S. UK population norms for EQ-5D. The University of York, Centre for Health Economics discussion paper 172. 1999. Centre for Health Economics, University of York; 1999. URL: www.euroqol.org/eq-5d/what-is-eq-5d.html (accessed 12 April 2013).
52. Dolan P, Gudex C, Kind P, Williams A. 1995. A social tariff for EuroQol: Results from a UK general population survey. York: Centre for Health Economics, University of York; pp. 1-19.
53. Petrou S. Methodological issues raised by preference-based approaches to measuring the health status of children. Health Econ 2003;12:697-702. http://dx.doi.org/10.1002/hec.775
54. Brazier JE, Yang Y, Tsuchiya A, Rowen DL. A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measures. Eur J Health Econ 2010;11:215-25. http://dx.doi.org/10.1007/s10198-009-0168-z
55. Longworth L, Rowen D. The use of mapping methods to estimate health state utility values. NICE DSU technical support document 10. Sheffield: Decision Support Unit, ScHARR, University of Sheffield; 2011.
56. Briggs A, Clark T, Wolstenholme J, Clarke P. Missing. presumed at random: cost-analysis of incomplete data. Health Econ 2003;12:377-92. http://dx.doi.org/10.1002/hec.766
57. Briggs AH, Gray AM. Handling uncertainty when performing economic evaluation of healthcare interventions. Health Technol Assess 1999;3(2).
58. Stinnett AA, Mullahy J. Net health benefits: A new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Making 1998;18:S65-80. http://dx.doi.org/10.1177/0272989X9801800209
59. Turner D, Broadley K, Ford, Kidd E, Powell C. Nebulised magnesium sulphate bronchodilator and bronchoprotective? London: British Pharmacological Society Proceedings; 2011. p. 26.
60. Szefler SJ, Zeiger RS, Haselkorn T, Mink DR, Kamath TV, Fish JE, et al. Economic burden of impairment in children with severe or difficult-to-treat asthma. Ann Allergy Asthma Immunol 2011;107:110-19. http://dx.doi.org/10.1016/j.anai.2011.04.008
61. Eiser C, Morse R. Quality-of-life measures in chronic diseases of childhood. Health Technol Assess 2001;5(4).
62. Babl FE, Sherrif N, Borland M, Acworth J, Neutze J, Krieser D, et al. Paediatric acute asthma management in Australia and New Zealand: practice patterns in the context of clinical practice guidelines. Arch Disease Child 2008;93:307-12. http://dx.doi.org/10.1136/adc.2007.125062
63. Yung M, South M. Randomised controlled trial of aminophylline for severe acute asthma. Arch Dis Child 1998;79:405-10. http://dx.doi.org/10.1136/adc.79.5.405
64. Davies G, Paton J, Beaton S, Young D, Lenney W. Children admitted with acute wheeze/asthma during. November 1998-2005: a national UK audit. Arch Dis Child 2008;93:952-8. http://dx.doi.org/10.1136/adc.2007.133868
65. Rodrigo G, Rodrigo C. Rapid onset asthma attack: a prospective cohort study about characteristics and response to emergency department treatment. Chest 2000;118:1547-52. http://dx.doi.org/10.1378/chest.118.6.1547
66. Woodruff P, Edmond S, Singh A, Carmargo C. Sudden onset severe acute asthma: clinical features and response to therapy. Acad Emerg Med 1998;5:695-701. http://dx.doi.org/10.1111/j.1553-2712.1998.tb02488.x
67. Barr R, Woodruff P, Clark S, Camargo C. Sudden onset asthma exacerbations: clinical features, response to therapy and 2-week follow up. Eur Resp J 2000;15:266-73. http://dx.doi.org/10.1034/j.1399-3003.2000.15b08.x
68. Martin A, Campbell D, Gluyas P, Coates J, Ruffin R, Roder D, et al. Characteristics of near fatal asthma in childhood. Pediatr Pulmonol 1995;20:1-8. http://dx.doi.org/10.1002/ppul.1950200102
69. Coates AL, Leung K, Vecellio L, Schuh S. Testing of nebulizers for delivering magnesium sulfate to pediatric asthma patients in the emergency department. Respir Care 2011;56:314-18. http://dx.doi.org/10.4187/respcare.00826
70. DiGregorio RV, Bessmertny O, Pringle G, Cohen H. Effect of nebulized magnesium sulfate on serum magnesium levels in asthmatic patients. ASHP Midyear Clinical Meeting 1999, vol. 34:[P-383E].
71. Coates JE. Lung function: assessment and application to medicine. 5th edn Oxford: Blackwell Scientific Publication; 1993.
72. Sur S, Cotty T, Kephart G, Hyma B, Colby T, Reed C, et al. Sudden onset asthma. A distinct entity with few eosinophils and more neutrophils in the airway mucosa. Am Rev Resp Dis 1993;148: 713-19.
73. Wang F, He X, Baines K, Gunawardhana L, Simpson J, Li F, et al. Different inflammatory phenotypes in adults and children with acute asthma. Eur Resp J 2011;38:567-74. http://dx.doi.org/10.1183/09031936.00170110
74. Simpson J, McElduff P, Gobson P. Assessment and reproducibility of non-eosinophilic asthma using induced sputum. Respiration 2010;79:147-51. http://dx.doi.org/10.1159/000245899
75. Davis WJ, Pang LM, Chernack WJ, Mellins RB. Terbutaline in the treatment of acute asthma in childhood. Chest 1977;72:614-17. http://dx.doi.org/10.1378/chest.72.5.614
76. Friede T, Keisser M. Sample size recalculation for binary data in internal pilot study designs: a review. Biometrical J 2006;48:537-55.
77. European Medicines Agency (EMA) (The European Agency for the Evaluation of Medical Products). Points to consider on adjustments for baseline covariates. 2003. URL: www.emea.europa.eu/pdfs/human/ewp/286399en.pdf (accessed 12 April 2013).
78. Pham B, Cranney A, Boers M, Verhoeven AC, Wells G, Tugwell P. Validity of area-under-the-curve analysis to summarize effect in rheumatoid arthritis clinical trials. J Rheumatol 1999;27:712-16.
79. Matthews JNS, Altman DG, Campbell MJ, Royston P. Analysis of serial measurements in medical research. BMJ 1990;300:230-5. http://dx.doi.org/10.1136/bmj.300.6719.230
80. Efron B, Tibshirani R. An introduction to the bootstrap. New York, NY: Chapman and Hall; 1993.
81. Wood AM, White IR, Thompson SG. Are missing outcome data adequately handled? A review of published randomized controlled trials in major medical journals. Clin Trials J 2004;1:368-76. http://dx.doi.org/10.1191/1740774504cn032oa
82. van Buuren S, Oudshoorn K. Flexible multiple imputation by MICE. Technical report PG/VGZ/99.054. Leiden: TNO Prevention and Health; 1999. URL: www.multiple-imputation.com/(accessed 12 April 2013).
83. Unnebrink K, Windeler J. Sensitivity analysis by worst and best case assessment: is it really sensitive? Drug Inf J 1999;33:835-9. http://dx.doi.org/10.1177/009286159903300324
84. Wood AM, White IR, Hillsdon M, Carpenter J. Comparison of imputation and modelling methods in the analysis of a physical activity trial with missing outcomes. Int J Epidemiol 2005;34:89-99. http://dx.doi.org/10.1093/ije/dyh297
85. Henderson R, Diggle P, Dobson A. Joint modelling of longitudinal measurements and event time data. Biostatistics 2000;1:465-80. http://dx.doi.org/10.1093/biostatistics/1.4.465
86. Clarke M, Hopewell S, Chalmers I. Reports of clinical trials should begin and end with up-to-date systematic reviews of other relevant evidence: a status report. J R Soc Med 2007;100:187-90. http://dx.doi.org/10.1258/jrsm.100.4.187